

Supplementary Online Content

Lansu J, Bovée JVMG, Braam P, et al. Dose reduction of preoperative radiotherapy in myxoid liposarcoma: a nonrandomized controlled trial. *JAMA Oncol*. Published online November 12, 2020. doi:10.1001/jamaoncol.2020.5865

eTable 1. Overview of the Wound Complication Definitions

eTable 2. Late Toxicity Overview

eTable 3. Overview of Bayesian Stopping Rule and Pathological Response Data per Patient

This supplementary material has been provided by the authors to give readers additional information about their work.

eTable 1. Overview of the Wound Complication Definitions

Wound complication type	Definition
Minor wound complication	Wound complication requiring no or non-invasive intervention such as oral antibiotics.
Moderate wound complication	Wound complication requiring secondary wound management without secondary operation such as an invasive procedure without general or regional anesthesia, readmission for wound care, or deep persistent packing.
Major wound complication	Wound complication requiring secondary operation such as debridement or operative drainage.
Wound complication requiring intervention	Wound complication meeting the criteria of a moderate or major wound complication.

eTable 2. Late Toxicity Overview

Toxicity	Grade 0	Grade 1	Grade 2	Grade 3
Fibrosis	50 (71%)	14 (20%)	6 (9%)	0
Joint stiffness	62 (89%)	7 (10%)	1 (1%)	0
Edema	47 (67%)	19 (27%)	2 (3%)	2 (3%)
Other	64 (91%)	5 (7%)	1 (1%)	0
Any toxicity	32 (46%)	28 (40%)	8 (11%)	2 (3%)

Late toxicity for 70 patients with ≥ 6 months follow-up, worst grade per patient. Late toxicity data of nine patients is lacking due to omitted surgery (n=2), amputation (n=1) and the follow up being < 6 months (n=6).

eTable 3. Overview of Bayesian Stopping Rule and Pathological Response Data per Patient

Study patient (center)	Required no. of responders to continue	Response by local pathologist	Hyalinization (%)	Fatty maturation (%)	Necrosis (%)	Vital tumor cells (%)	Response by central review pathologist	Final decision responding status	Cum. no. of responders
1 (A)	0	no	45	10	20	25	yes	yes	1
2 (A)	1	yes	10	80	9	1	yes	yes	2
3 (A)	1	yes	75	5	15	5	yes	yes	3
4 (A)	2	yes	N.A.	N.A.	N.A.	N.A.	N.A.	yes	4
5 (B)	2	yes	15	10	60	5	yes	yes	5
6 (A)	3	yes	65	20	0	15	yes	yes	6
7 (A)	3	yes	N.A.	N.A.	N.A.	N.A.	N.A.	yes	7
8 (B)	4	yes	95	0	0	5	yes	yes	8
9 (A)	4	yes	80	0	15	5	yes	yes	9
10 (A)	5	yes	20	5	0	75	no	no	9
11 (B)	6	yes	N.A.	N.A.	N.A.	N.A.	N.A.	yes	10
12 (A)	6	yes	90	5	0	5	yes	yes	11
13 (A)	7	yes	30	20	25	25	yes	yes	12
14 (C)	7	yes	40	40	10	10	yes	yes	13
15 (A)	8	yes	75	15	0	10	yes	yes	14
16 (A)	9	yes	90	0	0	10	yes	yes	15
17 (A)	9	yes	30	60	0	10	yes	yes	16
18 (D)	10	yes	85	10	0	5	yes	yes	17
19 (E)	10	no	30	0	0	70	no	no	17
20 (E)	11	yes	40	50	0	10	yes	yes	18
21 (E)	12	yes	60	35	0	10	yes	yes	19
22 (D)	12	no	50	35	0	15	yes	yes	20
23 (B)	13	yes	30	60	5	5	yes	yes	21
24 (B)	14	yes	30	30	30	10	yes	yes	22
25 (B)	14	yes	85	5	0	10	yes	yes	23
26 (B)	15	yes	60	5	30	5	yes	yes	24
27 (B)	15	yes	80	10	0	10	yes	yes	25
28 (F)	16	yes	95	0	0	5	yes	yes	26
29 (F)	17	yes	90	0	0	10	yes	yes	27
30 (F)	17	yes	90	0	0	10	yes	yes	28
31 (F)	18	yes	95	0	0	5	yes	yes	29
32 (F)	19	no	10	30	0	60	no	no	29
33 (F)	19	yes	30	20	0	50	no	no	29
34 (F)	20	no	20	10	30	40	yes	yes	30
35 (F)	20	yes	60	10	0	30	yes	yes	31
36 (F)	21	yes	90	0	0	10	yes	yes	32
37 (F)	22	yes	99	0	0	1	yes	yes	33
38 (D)	22	yes	N.A.	N.A.	N.A.	N.A.	N.A.	yes	34
39 (H)	23	yes	30	45	0	25	yes	yes	35
40 (A)	24	yes	45	30	10	15	yes	yes	36
41 (B)	24	yes	80	15	0	5	yes	yes	37
42 (E)	25	yes	80	10	0	10	yes	yes	38
43 (E)	26	no	45	25	0	30	yes	yes	39
44 (E)	26	yes	N.A.	N.A.	N.A.	N.A.	N.A.	yes	40

45 (C)	27	yes	25	25	30	20	yes	yes	41
46 (G)	27	yes	50	35	0	15	yes	yes	42
47 (B)	28	yes	25	60	0	15	yes	yes	43
48 (D)	29	yes	80	15	0	5	yes	yes	44
49 (A)	29	yes	70	10	5	15	yes	yes	45
50 (E)	30	no	5	65	0	30	yes	yes	46
51 (I)	31	no	55	20	5	20	yes	yes	47
52 (H)	31	yes	N.A.	N.A.	N.A.	N.A.	N.A.	yes	48
53 (G)	32	yes	50	40	0	10	yes	yes	49
54 (G)	33	yes	80	10	0	10	yes	yes	50
55 (A)	33	no	15	10	5	70	no	no	50
56 (B)	34	yes	10	80	0	10	yes	yes	51
57 (D)	35	yes	45	35	5	15	yes	yes	52
58 (A)	35	yes	30	10	0	60	no	no	52
59 (C)	36	yes	90	5	0	5	yes	yes	53
60 (D)	37	yes	70	5	0	25	yes	yes	54
61 (I)	37	no	40	55	0	5	yes	yes	55
62 (A)	38	yes	45	35	5	15	yes	yes	56
63 (D)	39	yes	10	80	0	10	yes	yes	57
64 (B)	39	yes	75	20	0	5	yes	yes	58
65 (H)	40	yes	10	35	35	20	yes	yes	59
66 (C)	40	yes	20	79	0	1	yes	yes	60
67 (B)	41	yes	55	30	0	15	yes	yes	61
68 (D)	42	yes	65	25	0	10	yes	yes	62
69 (C)	42	yes	N.A.	N.A.	N.A.	N.A.	N.A.	yes	63
70 (A)	43	yes	10	75	5	10	yes	yes	64
71 (G)	44	no	95	0	0	5	yes	yes	65
72 (I)	44	no	25	10	25	40	yes	yes	66
73 (A)	45	yes	80	10	5	5	yes	yes	67
74 (B)	46	yes	30	30	30	10	yes	yes	68
75 (I)	46	yes	80	19	0	1	yes	yes	69
76 (I)	47	no	0	5	15	80	no	no	69
77 (G)	48	yes	0	20	40	40	yes	yes	70

The posterior probability displayed in the third column, represents the posterior probability of $p \geq 0.7$ in case of the required number of responders to continue the trial.
Abbreviation: N.A.= not assessed.